12:12 PM EST, 12/02/2025 (MT Newswires) -- The European stock markets closed mixed in Tuesday trading as The Stoxx Europe edged 0.04% higher, Germany's DAX rose 0.51%, the FTSE 100 was off 0.01%, France's CAC declined 0.28%, and the Swiss Market Index increased 0.31%.

Euro area annual inflation was an estimated 2.2% in November, up from 2.1% in October, according to a flash estimate from Eurostat, the statistical office of the European Union. The reading was slightly higher than the 2.1% forecast by analysts, according to Bloomberg.

The highest annual rates were in Estonia (4.7%), Croatia (4.3%), and Austria (4.1%), while the lowest rates were in Cyprus (0.2%), France (0.8%), and Italy (1.1%).

Meanwhile, the euro area seasonally adjusted unemployment rate was unchanged at 6.4% in October from September, and was up from 6.3% a year earlier.

Analysts had expected a 6.3% unemployment rate, according to Bloomberg.

In the UK, annual house prices rose 1.8% in November to 272,998 pounds ($360,112), according to the Nationwide Housing Price Index, which outpaced the 1.4% increase expected by analysts, according to Bloomberg.

And in corporate news, British pharmaceutical giants AstraZeneca and GSK will be invited to join a UK government panel tasked with shaping a new drug-pricing framework to replace the Voluntary Scheme for Branded Medicines Pricing and Access, Sky News reported Tuesday, citing industry sources.

The working group, to be convened in the coming weeks, will assess options including outcomes-based pricing and links between pricing and UK research and development activity, the report said. The current pricing framework has been criticized by pharmaceuticals groups, which warn that they could delay or cancel billions in spending in Britain if it is not replaced.

Shares of AstraZeneca were off 0.3%, while GSK shares rose 1% on the FTSE 100 in London.

TotalEnergies is the leading bidder for a stake in Galp's major oil discovery offshore Namibia, Bloomberg reported Tuesday, citing sources familiar with the situation.

Galp is planning to sell half of its 80% stake in the Mopane field to a partner that would also become the project's operator, the report said, adding that the company expects to find a partner before the end of the year.

Shares of the French oil and gas company edged 0.1% lower in Paris.

Genmab's tisotumab vedotin drug has been approved by the UK's Medicines and Healthcare products Regulatory Agency to treat adults with cervical cancer that has come back or spread, the regulator said Tuesday.

The drug, which is intended for use if the disease worsens after anti-cancer treatment, is to be administered via an intravenous drip into the vein over 30 minutes once every three weeks, the regulator said.

Shares of the Danish biotech firm were off 0.4% in Copenhagen.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.